We are live on
!
Find out more
BG
Bellevue Group Portfolio holdings
AUM
$4.2B
1-Year Est. Return
54.85%
This Fund
S&P 500
This Quarter
Est. Return
-10.66%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$551M
AUM Growth
–
Cap. Flow
+$550M
Cap. Flow
% of AUM
99.74%
Top 10 Holdings %
Top 10 Hldgs %
31.05%
Holding
130
New
130
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$21.7M |
| 2 |
Gilead Sciences
GILD
|
+$21M |
| 3 |
Medtronic
MDT
|
+$20.8M |
| 4 |
Biogen
BIIB
|
+$20.2M |
| 5 |
Amgen
AMGN
|
+$15.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93% |
| 2 | Financials | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Globus Medical
GMED
$10.5B
| $2.08M | 0.38% |
+87,700
| New | +$2.14M |
|
|
QGENF
77
DELISTED
QIAGEN NV
QGENF
| $2.04M | 0.37% |
+91,500
| New | +$2.04M |
|
|
ZLTQ
78
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $2.04M | 0.37% |
+75,000
| New | +$1.77M |
|
|
LCI
79
DELISTED
Lannett Company, Inc.
LCI
| $1.93M | 0.35% |
+26,953
| New | +$2.85M |
|
80
AngioDynamics
ANGO
$558M
| $1.86M | 0.34% |
+151,400
| New | +$1.67M |
|
81
Healthcare Services Group
HCSG
$1.74B
| $1.84M | 0.33% |
+50,000
| New | +$1.74M |
|
|
ICPT
82
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.73M | 0.31% |
+13,500
| New | +$1.59M |
|
83
Novavax
NVAX
$1.35B
| $1.68M | 0.3% |
+16,250
| New | +$1.74M |
|
84
Teleflex
TFX
$5.96B
| $1.57M | 0.29% |
+10,010
| New | +$1.4M |
|
85
MacroGenics
MGNX
$285M
| $1.56M | 0.28% |
+83,000
| New | +$1.58M |
|
86
Alnylam Pharmaceuticals
ALNY
$35.7B
| $1.51M | 0.27% |
+24,000
| New | +$1.6M |
|
87
DaVita
DVA
$15.2B
| $1.47M | 0.27% |
+20,000
| New | +$1.35M |
|
|
JUNO
88
DELISTED
Juno Therapeutics, Inc.
JUNO
| $1.41M | 0.26% |
+37,000
| New | +$1.29M |
|
89
DexCom
DXCM
$29.6B
| $1.36M | 0.25% |
+80,000
| New | +$1.34M |
|
90
Prothena Corp
PRTA
$453M
| $1.28M | 0.23% |
+31,000
| New | +$1.21M |
|
91
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.26M | 0.23% |
+45,000
| New | +$981K |
|
|
RDUS
92
DELISTED
Radius Health, Inc.
RDUS
| $1.26M | 0.23% |
+40,000
| New | +$1.38M |
|
|
BLUE
93
DELISTED
bluebird bio
BLUE
| $1.23M | 0.22% |
+2,239
| New | +$1.38M |
|
94
Labcorp
LH
$23.2B
| $1.17M | 0.21% |
+11,640
| New | +$1.12M |
|
|
WMGI
95
DELISTED
Wright Medical Group Inc
WMGI
| $1.17M | 0.21% |
+70,309
| New | +$1.3M |
|
|
CLVS
96
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.01M | 0.18% |
+52,500
| New | +$1.11M |
|
|
QTNT
97
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $880K | 0.16% |
+2,500
| New | +$1.02M |
|
98
AbbVie
ABBV
$450B
| $857K | 0.16% |
+15,000
| New | +$836K |
|
|
INFI
99
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $843K | 0.15% |
+160,000
| New | +$979K |
|
|
ALDR
100
DELISTED
Alder Biopharmaceuticals
ALDR
| $808K | 0.15% |
+33,000
| New | +$764K |
|
Similar funds
WSFS
AC
HIP
DT
ATPW
BT
NCM
MSU
Bellevue Group's Q1 2016 Portfolio in Review
Q1 2016 is the first quarter with a 13F filing on record for Bellevue Group, which disclosed 130 positions worth $551M. Its ten largest holdings account for 31% of the portfolio.
Its largest position is Celgene Corp: 210,550 shares worth $21.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, followed by Financials.
- Bellevue Group's largest Q1 2016 buy was Celgene Corp: 210,550 shares worth $21.1M.
- Bellevue Group's ten largest holdings make up 31% of its $551M portfolio in Q1 2016.
- Bellevue Group disclosed 130 positions in Q1 2016, its first 13F filing on record.
Based on Bellevue Group's 13F filing for Q1 2016, filed 16 May 2016.